collaborations
Partnership Landscape
More than 40 RNAi-related transactions with total value of more than $5B have been completed since January 2005. These include:
 |
 |
|
The impressive RNAi therapeutic transaction history around preclinical stage assets and programs provides significant precedent for Silence’s potential for entering multi-million dollar deal with drug developer(s) |